IDIBELL on the media
IDIBELL launches its International Ph.D. Training Program
Today is the official presentation of the International Ph.D. Training Program and personalities involved in the program will give us some details about it.
World Cancer Day
At IDIBELL we know that research saves lives. That is why we work every day to do our bit in the search for a new treatment, a new method for early detection or understanding cancer-related processes.
Depletion of NOX4 protein improves liver regeneration
A group from IDIBELL, CIBEREHD and UB shows that mice that do not express the NOX4 protein recover liver tissue more quickly after resection.
A new algorithm classifies different types of sarcoma
An international study has developed a new algorithm that classifies a wide range of sarcomas according to their molecular patterns.
Xenograft Animal Models Recapitulate Genetic Behavior of Original Human Tumors
Researchers from IDIBELL and ICO have participated in a multicenter study, published in Nature Genetics, which shows that the implantation of human tumors in nude mice does not lead to additional DNA changes.
Aptadel, the new IDIBELL’s spinoff
Aptadel Therapeutics is a preclinical company co-founded by IDIBELL focused on developing a new platform for targeted therapy against cancer.
Cancer’s Key Vulnerabilities found by Big Data Analysis
The study lead by Columbia University, in collaboration with IDIBELL and ICO, analysed thousands of tumours. They found that the key genetic programs necessary for the survival of cancer cells are controlled by only 24 modules, each one comprising only a handful of Master Regulators proteins working in concert.
2020 highlights!
2020 is coming to its end, a year with great difficulties and challenges. However, this year, more than ever, we have proved the strength of our research.
Combined therapy could be a solution for EGFR inhibitor-resistant skin squamous cell cancers
A team from IDIBELL has deciphered the molecular mechanisms responsible for resistance to EGFR inhibitors and offers new therapeutic strategies.
Iron treatment reduces the risk of hospitalization in people with heart deficiencies
Results, released simultaneously at the American Heart Association (AHA) 2020 virtual conference and in the journal The Lancet, show that patients who received the iron supplement were 26% less likely to be readmitted to the hospital for heart failure compared to the control group.